Details:
The allowed patent application focuses on novel antibodies which target pE3-Aβ, a specific truncated form of amyloid beta and are linked to the company’s project AD1503.
Lead Product(s): AD1503
Therapeutic Area: Neurology Product Name: AD1503
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021